A C Bertagnolli1, E Ferreira, E J Dias, G D Cassali. 1. University of Rio Doce Valley, Governador Valadares, Minas Gerais, BrazilLaboratory of Comparative Pathology, Department of General Pathology, Institute of Biological Science, Federal University of Minas Gerais, Brazil Laboratory of Comparative Pathology, Department of General Pathology, Institute of Biological Science, Federal University of Minas Gerais, 486 31270-901 Belo Horizonte Minas Gerais, Brazil; cassalig@icb.ufmg.br.
Abstract
BACKGROUND: Benign mixed tumours (BMTs) are frequently found in the mammary glands of female dogs, but the factors determining malignant transformation in these tumours are unknown. OBJECTIVE: To evaluate the expression of the oncoproteins, human epidermal growth factor receptor 2 (HER-2) and epidermal growth factor receptor (EGFR), in 46 carcinomas in BMTs (CBMTs) and to verify their possible association with the malignancy of the tumours. METHODS: Immunohistochemical expression was analysed in benign and malignant components separately, and then compared with 74 cases of BMTs. RESULTS: Among the CBMTs, positivity for HER-2 was found in the benign histological component of 4.3% (2/46), in the malignant epithelial non-invasive component of 14.8% (4/27) and in the malignant invasive epithelial component of 13.6% (6/44) of cases. Two of the 24 (8.3%) BMTs were positive for HER-2. There was no relationship between HER-2 and the tumour components. There was no significant difference between BMTs and CBMTs. Positivity for EGFR was found in the benign component of 17.4% (8/46) of the CBMTs, in the malignant epithelial non-invasive component of 40.7% (11/27%) and in the invasive epithelial malignant component of 45.4% (20/44). EGFR positivity was significantly associated with the invasive component of CBMTs. CONCLUSION: EGFR may contribute to malignant epithelial transformation of BMTs. In contrast, HER-2 overexpression may not be associated with the acquisition of a malignant epithelial phenotype.
BACKGROUND: Benign mixed tumours (BMTs) are frequently found in the mammary glands of female dogs, but the factors determining malignant transformation in these tumours are unknown. OBJECTIVE: To evaluate the expression of the oncoproteins, human epidermal growth factor receptor 2 (HER-2) and epidermal growth factor receptor (EGFR), in 46 carcinomas in BMTs (CBMTs) and to verify their possible association with the malignancy of the tumours. METHODS: Immunohistochemical expression was analysed in benign and malignant components separately, and then compared with 74 cases of BMTs. RESULTS: Among the CBMTs, positivity for HER-2 was found in the benign histological component of 4.3% (2/46), in the malignant epithelial non-invasive component of 14.8% (4/27) and in the malignant invasive epithelial component of 13.6% (6/44) of cases. Two of the 24 (8.3%) BMTs were positive for HER-2. There was no relationship between HER-2 and the tumour components. There was no significant difference between BMTs and CBMTs. Positivity for EGFR was found in the benign component of 17.4% (8/46) of the CBMTs, in the malignant epithelial non-invasive component of 40.7% (11/27%) and in the invasive epithelial malignant component of 45.4% (20/44). EGFR positivity was significantly associated with the invasive component of CBMTs. CONCLUSION:EGFR may contribute to malignant epithelial transformation of BMTs. In contrast, HER-2 overexpression may not be associated with the acquisition of a malignant epithelial phenotype.
Authors: Gustavo Meirelles Ribeiro; Angélica Cavalheiro Bertagnolli; Rafael Malagoli Rocha; Geovanni Dantas Cassali Journal: Vet Med Int Date: 2012-09-13
Authors: Thaynan Cunha Vieira; Evelyn Ane Oliveira; Bárbara Jaime Dos Santos; Fernanda Rezende Souza; Emerson Soares Veloso; Cristiana Buzelin Nunes; Helen Lima Del Puerto; Geovanni Dantas Cassali Journal: Front Vet Sci Date: 2022-09-12
Authors: Karine A Damasceno; Angélica C Bertagnolli; Alessandra Estrela-Lima; Lorena Gr Ribeiro; Bruna S Rabelo; Cecília B Campos; André Lb Barros; Geovanni D Cassali Journal: BMC Vet Res Date: 2012-10-20 Impact factor: 2.741